Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2020 | APR-246 combination treatments in TP53-mutant R/R NHLs

Meghan Thompson • 8 Dec 2020
ASH 2020
Chronic Lymphocytic Leukemia Leukemia Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Antibodies Eprenetapopt Ibrutinib Rituximab Venetoclax

Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses an upcoming Phase 1 study (NCT04419389) aiming to evaluate the efficacy and safety of APR-246 in combination with ibrutinib or a venetoclax-based therapy in patients with TP53-mutant relapsed/refractory (R/R) non-Hodgkin lymphomas (NHLs), including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Enrollment for this trial is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Curio Science

More from Meghan Thompson

Advice for young investigators entering the CLL space and key areas of interest
1:43
Advice for young investigators entering the CLL space and key areas of interest
Meghan Thompson • 4 Sep 2025
An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials
14:48
An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials
Alexey Danilov et al. • 28 Sep 2025
Novel agents showing promise for the treatment of double-refractory CLL
1:18
Novel agents showing promise for the treatment of double-refractory CLL
Meghan Thompson • 5 Sep 2025
How to approach sequencing in CLL amid expanding treatment options
1:22
How to approach sequencing in CLL amid expanding treatment options
Meghan Thompson • 5 Sep 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals